Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Kane Biotech Inc V.KNE

Alternate Symbol(s):  KNBIF

Kane Biotech Inc. is a Canada-based biotechnology company engaged in the research, development and commercialization of technologies and products that prevent and remove microbial biofilms. The Company has a portfolio of biotechnologies, intellectual property (66 patents and patents pending, trade secrets and trademarks) and products developed by its own biofilm research expertise and acquired from research institutions. DispersinB, coactiv+, coactiv+, DermaKB, DermaKB Biofilm, and revive are trademarks of the Company. Its patented coactiv+ technology is specifically formulated to destabilize biofilm and create an environment for fast wound healing. In Wound Care & Surgical applications, in addition to revyve Antimicrobial Wound Gel, it is developing follow-on products with three applications: coactiv+ Antimicrobial Surgical Hydrogel, coactiv+ Antimicrobial Wound Gel Spray, and coactiv+ Antimicrobial Wound Rinse. The Company's other biofilm disruption technology is DispersinB.


TSXV:KNE - Post by User

Bullboard Posts
Post by TechnicalBuyon Apr 06, 2011 9:31am
439 Views
Post# 18392153

Huge interest in Kane

Huge interest in KaneFinancing increased to 20M from 12M shares. This will be enough money to pay for trials and even kick start some other programs. Great news!

WINNIPEG,MANITOBA--(Marketwire - April 6, 2011) - Kane Biotech Inc. (TSX VENTURE:KNE), abiotechnology company engaged in the development and commercialization ofproducts that prevent and remove microbial biofilms (the "Company"),today announces that it has increased the current private placement offering(the "Offering"), first reported on March 30, 2011, from a maximum of12,500,000 units ("Units") to 20,000,000 Units at a price of
.12per Unit, for total gross proceeds of up to $2,400,000. As previouslyannounced, each Unit will be comprised of one common share of the Company (a"Share") and one Share purchase warrant (a "Warrant"). EachWarrant will expire 18 months from the date the Warrant is issued and willentitle the holder to purchase one Share at a price of
.17 per Share.

TB
Bullboard Posts